|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PLCL2 |
Gene summary for PLCL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PLCL2 | Gene ID | 23228 |
| Gene name | phospholipase C like 2 | |
| Gene Alias | PLCE2 | |
| Cytomap | 3p24.3 | |
| Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | Q9UPR0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23228 | PLCL2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.48e-04 | -4.09e-01 | 0.0155 |
| 23228 | PLCL2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.66e-04 | 2.62e-01 | -0.1954 |
| 23228 | PLCL2 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.23e-04 | -4.29e-01 | 0.096 |
| 23228 | PLCL2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.30e-09 | -3.99e-01 | 0.0674 |
| 23228 | PLCL2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.64e-20 | -5.07e-01 | 0.294 |
| 23228 | PLCL2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.81e-15 | -4.88e-01 | 0.3859 |
| 23228 | PLCL2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 9.12e-03 | -5.01e-01 | 0.2585 |
| 23228 | PLCL2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.38e-17 | -5.04e-01 | 0.3005 |
| 23228 | PLCL2 | A015-C-203 | Human | Colorectum | FAP | 2.48e-12 | -3.35e-01 | -0.1294 |
| 23228 | PLCL2 | A015-C-204 | Human | Colorectum | FAP | 1.00e-03 | -3.62e-01 | -0.0228 |
| 23228 | PLCL2 | A002-C-201 | Human | Colorectum | FAP | 1.15e-02 | -2.32e-01 | 0.0324 |
| 23228 | PLCL2 | A001-C-119 | Human | Colorectum | FAP | 1.68e-03 | -3.77e-01 | -0.1557 |
| 23228 | PLCL2 | A001-C-108 | Human | Colorectum | FAP | 1.46e-06 | -3.27e-01 | -0.0272 |
| 23228 | PLCL2 | A002-C-205 | Human | Colorectum | FAP | 9.70e-10 | -3.64e-01 | -0.1236 |
| 23228 | PLCL2 | A015-C-006 | Human | Colorectum | FAP | 3.92e-04 | -2.78e-01 | -0.0994 |
| 23228 | PLCL2 | A015-C-106 | Human | Colorectum | FAP | 1.08e-03 | -2.60e-01 | -0.0511 |
| 23228 | PLCL2 | A002-C-114 | Human | Colorectum | FAP | 9.44e-09 | -4.14e-01 | -0.1561 |
| 23228 | PLCL2 | A015-C-104 | Human | Colorectum | FAP | 1.45e-11 | -1.73e-01 | -0.1899 |
| 23228 | PLCL2 | A001-C-014 | Human | Colorectum | FAP | 5.65e-04 | -2.28e-01 | 0.0135 |
| 23228 | PLCL2 | A002-C-016 | Human | Colorectum | FAP | 5.01e-09 | -3.08e-01 | 0.0521 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0051098 | Colorectum | AD | regulation of binding | 126/3918 | 363/18723 | 6.01e-10 | 4.88e-08 | 126 |
| GO:0051099 | Colorectum | AD | positive regulation of binding | 66/3918 | 173/18723 | 1.47e-07 | 6.64e-06 | 66 |
| GO:0043393 | Colorectum | AD | regulation of protein binding | 68/3918 | 196/18723 | 5.17e-06 | 1.34e-04 | 68 |
| GO:0032092 | Colorectum | AD | positive regulation of protein binding | 33/3918 | 85/18723 | 1.22e-04 | 1.78e-03 | 33 |
| GO:0018105 | Colorectum | AD | peptidyl-serine phosphorylation | 88/3918 | 315/18723 | 1.73e-03 | 1.43e-02 | 88 |
| GO:0018209 | Colorectum | AD | peptidyl-serine modification | 92/3918 | 338/18723 | 3.19e-03 | 2.36e-02 | 92 |
| GO:0048017 | Colorectum | AD | inositol lipid-mediated signaling | 53/3918 | 182/18723 | 5.35e-03 | 3.52e-02 | 53 |
| GO:0048015 | Colorectum | AD | phosphatidylinositol-mediated signaling | 52/3918 | 178/18723 | 5.37e-03 | 3.54e-02 | 52 |
| GO:0106106 | Colorectum | AD | cold-induced thermogenesis | 43/3918 | 144/18723 | 7.05e-03 | 4.31e-02 | 43 |
| GO:0120161 | Colorectum | AD | regulation of cold-induced thermogenesis | 43/3918 | 144/18723 | 7.05e-03 | 4.31e-02 | 43 |
| GO:1990845 | Colorectum | AD | adaptive thermogenesis | 46/3918 | 157/18723 | 7.97e-03 | 4.73e-02 | 46 |
| GO:00510982 | Colorectum | MSS | regulation of binding | 113/3467 | 363/18723 | 3.55e-09 | 2.41e-07 | 113 |
| GO:00510992 | Colorectum | MSS | positive regulation of binding | 59/3467 | 173/18723 | 7.11e-07 | 2.53e-05 | 59 |
| GO:00433932 | Colorectum | MSS | regulation of protein binding | 62/3467 | 196/18723 | 6.44e-06 | 1.69e-04 | 62 |
| GO:00320921 | Colorectum | MSS | positive regulation of protein binding | 29/3467 | 85/18723 | 4.44e-04 | 5.32e-03 | 29 |
| GO:00181052 | Colorectum | MSS | peptidyl-serine phosphorylation | 81/3467 | 315/18723 | 8.92e-04 | 9.12e-03 | 81 |
| GO:00182091 | Colorectum | MSS | peptidyl-serine modification | 84/3467 | 338/18723 | 2.12e-03 | 1.79e-02 | 84 |
| GO:00510984 | Colorectum | FAP | regulation of binding | 81/2622 | 363/18723 | 1.04e-05 | 2.97e-04 | 81 |
| GO:00181053 | Colorectum | FAP | peptidyl-serine phosphorylation | 71/2622 | 315/18723 | 2.51e-05 | 5.82e-04 | 71 |
| GO:00510994 | Colorectum | FAP | positive regulation of binding | 44/2622 | 173/18723 | 4.52e-05 | 9.40e-04 | 44 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PLCL2 | SNV | Missense_Mutation | novel | c.2200N>T | p.Arg734Trp | p.R734W | Q9UPR0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| PLCL2 | SNV | Missense_Mutation | c.2339A>T | p.Asp780Val | p.D780V | Q9UPR0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |
| PLCL2 | SNV | Missense_Mutation | c.727G>C | p.Val243Leu | p.V243L | Q9UPR0 | protein_coding | deleterious(0.01) | possibly_damaging(0.78) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PLCL2 | SNV | Missense_Mutation | novel | c.2996N>C | p.Lys999Thr | p.K999T | Q9UPR0 | protein_coding | deleterious(0) | possibly_damaging(0.756) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
| PLCL2 | SNV | Missense_Mutation | c.3125N>C | p.Ile1042Thr | p.I1042T | Q9UPR0 | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| PLCL2 | SNV | Missense_Mutation | c.1939N>C | p.Ser647Pro | p.S647P | Q9UPR0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PLCL2 | SNV | Missense_Mutation | c.2425N>T | p.Pro809Ser | p.P809S | Q9UPR0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PLCL2 | SNV | Missense_Mutation | novel | c.470N>T | p.Arg157Ile | p.R157I | Q9UPR0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PLCL2 | SNV | Missense_Mutation | novel | c.2042N>T | p.Arg681Ile | p.R681I | Q9UPR0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PLCL2 | SNV | Missense_Mutation | novel | c.1623N>G | p.Asp541Glu | p.D541E | Q9UPR0 | protein_coding | tolerated(0.48) | benign(0.163) | TCGA-AN-A0FJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |